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A B S T R A C T
The aims of this study were to: 1) determine prevalence of anogenital and oral HPV, 2) determine concordance
between HPV at anal, perianal, scrotal/penile, and oral sites; and 3) describe factors associated with anogenital
HPV types targeted by the 9-valent vaccine. Data were collected from 2012 to 2015 among men who have sex
with men 18–26 years of age enrolled in a vaccine trial (N=145). Penile/scrotal, perianal, anal, and oral
samples were tested for 61 HPV types. Logistic regression was used to identify factors associated with types in
the 9-valent vaccine. Participants’ mean age was 23.0 years, 55.2% were African-American, and 26.2% were
Hispanic; 93% had anal, 40% penile, and 6% oral HPV. Among those with anogenital infection, 18% had HPV16.
Concordance was low between anogenital and oral sites. Factors independently associated with a 9-valent
vaccine-type HPV were: race (African-American vs. White, OR=2.67, 95% CI=1.11–6.42), current smoking (yes
vs. no, OR=2.37, 95% CI=1.03–5.48), and number of recent receptive anal sex partners (2+ vs. 0, OR=3.47,
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T
95% CI=1.16–10.4). Most MSM were not infected with HPV16 or HPV18, suggesting that they may still benefit
from HPV vaccination, but anogenital HPV was very common, highlighting the importance of vaccinating men
before sexual initiation.
Clinical trial number: NCT01209325
1. Introduction
Human papillomavirus (HPV) infection causes anogenital and or-
opharyngeal cancers in both men and women. HIV-infected individuals
are at substantially higher risk for HPV-associated cancers than HIV-
uninfected individuals, and HIV-infected men who have sex with men
(MSM) are at particularly high risk for anal cancer [6,31,33]. Colon-
Lopez et al. reported that among 447,953 people with HIV infection in
the U.S., anal cancer incidence was markedly higher than in the general
population (standardized incidence ratio 19.1, 95% CI 18.1–20.0) and
was highest among MSM [3].
Three prophylactic HPV vaccines that target HPV16 and HPV18, the
types most likely to cause anal cancer, have been licensed for use: a 2-
valent (HPV16, 18), 4-valent (HPV6, 11, 16, 18) and 9-valent (HPV6,
11, 16, 18, 31, 33, 45, 52, 58) vaccine. Only the latter is currently
available in the U.S. The U.S. Advisory Committee on Immunization
Practices (ACIP) recommends routine HPV vaccination of men at age
11–12 years, with catch-up vaccination for all men 13–21 years of age
and for men at high risk for HPV up to 26 years of age [20,32]. How-
ever, vaccination rates in men are relatively low [36]. In one U.S. study
conducted in 2011, only 4.9% of MSM between 18 and 26 years of age
had received at least one HPV vaccine dose [21]. Low vaccination rates
may be due in part to inadequate awareness and understanding, among
both clinicians and MSM, of the epidemiology of HPV in MSM and
assumptions that the HPV vaccine will not be effective in men who are
already sexually active [25].
Recent studies have examined the prevalence and risk factors for
HPV in HIV-infected MSM [4,10,13,14,17–19,22,24,27,34,35,37,
38,41]. However, few of these studies have recruited only young HIV-
infected men, and little is known about HPV infection in this high-risk
population. Characterization of type-specific HPV prevalence in young
HIV-infected MSM is critical in order determine whether vaccination is
likely to be effective. In addition, few previous studies have determined
concordance between multiple anogenital and oral sites and examined
HPV genotype variants among HIV-infected MSM. Information about
concordance has implications for understanding the accuracy of sam-
pling at only one site for anogenital HPV, the extent of self-inoculation
between sites, and susceptibility of different anatomic areas to specific
HPV types [41]. Information about sequence variation within HPV
types is important in that it has been shown to be associated with dif-
ferences in viral persistence and the risk of cervical cancer
[26,29,39,45]. Genotype variants may also contribute to racial and
ethnic differences in the prevalence of HPV-associated cancers. We
therefore conducted a study to examine the epidemiology of HPV at
anogenital and oral sites in young, unvaccinated HIV-infected MSM
participating in an HPV vaccine clinical trial. The aims of this study
were to: 1) determine prevalence of anogenital (anal, perianal, and
scrotal/penile) and oral HPV, 2) describe HPV16, HPV18, and HPV31
genotype variants, 3) determine concordance between HPV at anal,
perianal, scrotal/penile, and oral sites; and 4) describe factors (demo-
graphic, behavioral, immunologic, and virologic) associated with ano-
genital HPV types targeted by the 9-valent vaccine, including HPV16/
18, in this population.
2. Material and methods
We conducted a phase II, open-label, multi-center trial of the
quadrivalent HPV (HPV6, 11, 16, 18) vaccine in 13- to 26-year-old HIV-
infected MSM. Additional inclusion criteria included: if receiving
antiretroviral therapy, receipt of therapy for at least 3 months and no
change in the prior 30 days; if not receiving antiretroviral therapy, CD4
count> 350 cells/mm3 prior to study entry; normal anal cytology
within 90 days and no HSIL on biopsy; absolute neutrophil count>
750 cells/mm3, hemoglobin > 9.0 g/dL, platelet count > 100,000/
mm3, liver function tests less than 3 times the upper limit of normal,
creatinine clearance > 60mL/min, and Karnofsky performance score
> 70 within 45 days prior to entry. Data from the baseline visit were
analyzed for this study. This trial was conducted by the AIDS
Malignancy Consortium (AMC-072, NCT01209325) in collaboration
with the Adolescent Medicine Trials Network for HIV/AIDS
Interventions (ATN). Participants were recruited between 2012 and
2015 from 15 U.S. sites.
Participants underwent screening with anal cytology and high-re-
solution anoscopy by trained clinicians. Visible suspicious lesions were
biopsied. Those positive for high-grade squamous intraepithelial lesions
(HSIL) on biopsy at baseline were excluded from participation in the
trial and were not included in this analysis. Participants who completed
the first study visit (N=145) completed a survey instrument at the first
visit assessing demographic characteristics, knowledge about HPV and
HPV vaccines, smoking and sexual behaviors. Recent CD4+ count and
HIV viral load data were collected and participants were tested at
baseline for gonorrhea and chlamydia using a urine specimen (tested
using a nucleic acid amplification test performed locally at sites).
Written informed consent was obtained, and the Institutional Review
Board for each participating site approved the study.
Penile/scrotal, perianal and anal samples for HPV DNA testing were
collected as follows. The penis (shaft, glans and corona), scrotal skin,
and perianal skin were gently abraded with 600 grit emery paper and
then swabbed with a Dacron swab moistened with sterile saline. The
intra-anal HPV sample was collected using a Dacron swab after a swab
for cytology testing. All swabs were placed into a container of STM
(Specimen Transport Medium, DIGENE, Gaithersburg MD) and stored
at −80 °C until shipment and testing. Throat wash samples (participant
swished/gargled with 10mL of Scope mouthwash) were collected for
oral HPV testing. Samples were centrifuged, and the pellet and super-
natant were stored at −80 °C until shipment and testing. HPV DNA
extraction was performed on all samples. Briefly, the anogenital sam-
ples were heat-inactivated followed by addition of Proteinase K and an
ammonium acetate/ethanol mixture. They were frozen at −20 °C
overnight and then centrifuged to obtain the pellet. The samples were
eluted in Tris-EDTA buffer. DNA from oral samples was extracted using
a modified Puregene (Qiagen) assay [5].
MY09/MY11 L1 consensus primers were used to amplify HPV se-
quences as described previously [30]. Beta-globin primers were used as
an internal control to test for adequacy of DNA. Samples were dot-
blotted onto a membrane and probed for HPV DNA using a chemilu-
minescent procedure with a consensus probe mixture. Samples were
then analyzed for the presence of 33 individual HPV types, and a mix of
28 additional types. Samples that were negative for beta-globin were
excluded from analysis.
Finally, we determined the prevalence of anogenital HPV16, 18, and
31 genotype variants. Variant classification was determined by se-
quencing of the E6 regions of HPV16, 18, and 31. The E6 gene of HPV
16 and HPV 18 were amplified using a previously described protocol
and primer set [40,44]. The HPV31 E6 region was amplified by single-
tube nested PCR using the outer primers GGAGTGACCGAAAGTGGT
GAA (forward) and CTTGTCCAGCTGGACTGTCTA (reverse), and inner
primers ACGGTTGGTATATAAAG (forward) and TCGGGTAATTGCT
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CAT (reverse). PCR products were then visualized by gel electrophor-
esis to confirm a single band. The PCR product was cleaned with
MCMag Beads (MCLabs, South San Francisco) and sequenced in both
directions using the internal primers of the nested PCR. Sequences were
aligned to the reference sequence for each type and variant groups
determined by previous published groupings.
We first examined participant characteristics and prevalence of
anogenital and oral HPV using descriptive statistics. HPV infection was
analyzed by site (anal, perianal, scrotal/penile, and oral) and by type:
any HPV (positive for at least one HPV type); HPV types in the 2-valent
(HPV16, 18), 4-valent (HPV6, 11, 16, 18), and 9-valent (HPV6, 11, 16,
18, 31, 33, 35, 45, 52) vaccines; high-risk HPV (positive for at least one
high-risk type), and individual HPV types. We then determined con-
cordance between anogenital sites for those participants who had
evaluable HPV results at all three sites, and between any anogenital site
and the oral site for those participants who had evaluable results for all
four of those sites. We also examined associations between HPV geno-
type variants and race/ethnicity using a Fisher's exact test. Using uni-
variable logistic regression analysis, we examined associations between
the following factors and positivity for one of the types in the 9-valent
HPV vaccine, as well as positivity for HPV16 and/or HPV18, by ano-
genital site: age, race, ethnicity, smoking, sexual behaviors, concurrent
chlamydia or gonorrhea infection, CD4+T-cell count, and HIV viral
load. Variables associated with HPV in univariable analyses at p< .10
were entered into separate multivariable models by HPV detection site
(anal, perianal, scrotal/penile, any site): variables associated with HPV
at p > 0.10 after adjusting for other variables were removed from the
multivariable model. Analyses were conducted using SAS version 9.4.
3. Results
The median age of participants (N= 145) was 23 years (range
18–26 years). Although 13–26 year-olds were eligible, no one under age
18 years was enrolled. HIV transmission was through homosexual
contact in 137 (94.5%), homosexual and heterosexual contact in 5
(3.4%), any sexual contact and IV drug use in 2 (1.4%) and perinatal
infection in 1 (0.7%). Of the original 260 HIV-infected MSM screened,
94 (36%) were excluded from enrollment because of a diagnosis of anal
HSIL and an additional 21 did not meet other inclusion criteria or did
not enroll for other reasons. Of the 145 who were enrolled, just over
half (55.2%) were African-American, 26.2% were Hispanic, and 45.3%
reported current smoking (Table 1). More than 90% of participants
reported having had sexual intercourse with a male partner in the past 6
months: 55.5% reported at least 2 receptive male partners during this
time. Urine specimens were positive for gonorrhea or chlamydia in 6
(4.3%) of participants: 1 was positive for both and 5 for chlamydia only.
Fewer than 10% of participants had a CD4+T-cell count of ≤350
cells/mm3 and 91% had an HIV viral load of< 400 copies/mL.
Almost all participants (95%) were infected with at least one HPV
type at an anogenital site: 93% at the anal canal, 76% at the perianus,
Table 1
Baseline characteristics of the study sample (n= 145).
Variable Totala Categories N (%) Median (range)
Age (years) 145 23 (18–26)
22–26 115 (79.3)
18–21 30 (20.7)
Race 145 White 47 (32.4)
African-American 80 (55.2)
Other 18 (12.4)
Ethnicity 145 Non-Hispanic 107 (73.8)
Hispanic 38 (26.2)
Current smoking 137 No (not at all) 75 (54.7)
Yes (some days/every day) 62 (45.3)
Last receptive anal intercourse 135 Over 6 months ago 25 (18.5)
1–6 months ago 36 (26.7)
Within the past month 74 (54.8)
Sexual intercourse with male partner, past 6 months 137 No 13 (9.5)
Yes 124 (90.5)
Number of male sexual partners, past 6 months 137 0 13 (9.5)
1 48 (35.0)
2+ 76 (55.5)
Number of receptive anal male sexual partners, past 6 months 127 0 16 (12.6)
1 53 (41.7)
2+ 58 (45.7)
Frequency of condom use during receptive anal sex with male partner, past 6 months 128 No anal sex past 6 months 16 (12.5)
Every time 51 (39.8)
Sometimes/never 61 (47.7)
Number of male oral sexual partners, past 6 monthsb 136 0 15 (11.0)
1 54 (39.7)
2+ 67 (49.3)
Frequency of condom use during oral sex, past 6 months 137 No oral sex past 6 months 15 (10.9)
Sometimes/always 36 (26.3)
Never 86 (62.8)
Had sexual intercourse with female partner, past 6 months 137 Yes 8 (5.8)
No 129 (94.2)
Chlamydia and/or gonorrhea (urethral) infection at baseline 141 Yes 6 (4.3)
No 135 (95.7)
CD4+ count (cells/mm3) 144 594 (237–1520)
≤ 350 14 (9.7)
> 350 130 (90.3)
HIV viral load (copies/mL) 144 0 (0–63,000)
< 400 131 (91.0)
≥ 400 13 (9.0)
a Not all N= 145 due to missing data and skip patterns.
b Defined as number of men to whom the participant gave oral sex.
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and 40% at the penis/scrotum (Table 2). The most commonly identified
type at any site was HPV6, present in 39% of young men; HPV11 was
present in 17%. The most common high-risk type was HPV16, identified
in 20%; HPV18 was identified in 11%. Fifty-seven percent of partici-
pants were infected with at least one HPV type targeted by the 4-valent
vaccine, 70% with a type targeted by the 9-valent vaccine, and 70%
with at least one high-risk type. Oral HPV was identified in 6% of
participants: 3 were infected with high-risk types (2 with HPV35, 1 with
HPV39), 3 with HPV32/42, and none with HPV16.
HPV16, HPV18, and HPV31 genotype variants were detected with
different frequencies by race, though differences were not statistically
significant (Table 3). Among African-American men, 9/24 (38%)
known HPV16 variants were of African lineage and 14/24 (58%) were
of European lineage. Among White men, 1/10 (10%) of HPV16 variants
were of the African lineage and 9/10 (90%) were of the European
lineage. Among African-American men, 5/13 (38%) HPV18 variants
were of African lineage and 6/13 (46%) were of European lineage,
while among White men, 1/5 (20%) were of African lineage and 2/5
(40%) were of European lineage. Finally, among African-American
men, 3/9 (33%) HPV31 genotype variants were type A, 4/9 (44%) were
type B, and 1/9 (11%) was type C, while among White men, 5/6 (83%)
were type A, 0 were type B, and 1/6 (17%) was type C: the A lineage is
found worldwide while the B and C lineages are found primarily in
Africa [2].
Table 2
Prevalence of anogenital HPV types (at any anogenital site and stratified by site) and oral HPV types.
Any Anogenital Sitea Analb Perianalc Penile/Scrotald Oral
(n=141) (n=137) (n=136) (n=133) (n=139)
HPV type N (%) N (%) N (%) N (%) N (%)
Any HPV typee 134 (95) 128 (93) 104 (76) 53 (40) 9 (6)
2-valent vaccine types (16, 18) 35 (25) 34 (25) 15 (11) 2 (2) 0 (0)
4-valent vaccine types (6, 11, 16, 18) 81 (57) 73 (53) 46 (34) 14 (11) 0 (0)
9-valent vaccine types (6, 11, 16, 18, 31, 33, 45, 52, 58) 99 (70) 93 (68) 59 (43) 16 (12) 0 (0)
High-risk types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, 82) 98 (70) 95 (69) 51 (38) 11 (8) 3 (2)
HPV6f 55 (39) 49 (36) 26 (19) 8 (6) 0 (0)
HPV11f 24 (17) 17 (12) 15 (11) 6 (5) 0 (0)
HPV16f 26 (18) 25 (18) 9 (7) 2 (2) 0 (0)
HPV18f 15 (11) 14 (10) 6 (4) 0 (0) 0 (0)
HPV31g 12 (9) 12 (9) 2 (1) 0 (0) 0 (0)
HPV33g 12 (9) 12 (9) 5 (4) 0 (0) 0 (0)
HPV35 19 (13) 18 (13) 5 (4) 0 (0) 2 (1)
HPV39 11 (8) 10 (7) 3 (2) 1 (1) 1 (1)
HPV45g 14 (10) 13 (9) 6 (4) 0 (0) 0 (0)
HPV51 21 (15) 19 (14) 8 (6) 4 (3) 0 (0)
HPV52g 14 (10) 13 (9) 7 (5) 1 (1) 0 (0)
HPV56 8 (6) 7 (5) 3 (2) 1 (1) 0 (0)
HPV58g 22 (16) 19 (14) 7 (5) 1 (1) 0 (0)
HPV59 13 (9) 13 (9) 7 (5) 1 (1) 0 (0)
HPV68 13 (9) 12 (9) 4 (3) 2 (2) 0 (0)
HPV73 6 (4) 6 (4) 1 (1) 1 (1) 0 (0)
HPV82 15 (11) 9 (7) 5 (4) 3 (2) 0 (0)
HPV26/69h 6 (4) 6 (4) 1 (1) 0 (0) 0 (0)
HPV30 8 (6) 7 (5) 3 (2) 0 (0) 0 (0)
HPV32/42 13 (9) 11 (8) 4 (3) 1 (1) 3 (2)
HPV34 4 (3) 3 (2) 0 (0) 1 (1) 0 (0)
HPV53 20 (14) 19 (14) 7 (5) 1 (1) 0 (0)
HPV54 10 (7) 10 (7) 7 (5) 1 (1) 0 (0)
HPV57/2/27 1 (1) 0 (0) 0 (0) 1 (1) 0 (0)
HPV61 12 (9) 12 (9) 7 (5) 0 (0) 0 (0)
HPV62 19 (13) 17 (12) 11 (8) 4 (3) 0 (0)
HPV66 4 (3) 2 (1) 2 (1) 0 (0) 0 (0)
HPV67 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
HPV70 7 (5) 6 (4) 3 (2) 0 (0) 0 (0)
HPV71 2 (1) 1 (1) 1 (1) 0 (0) 1 (1)
HPV72 8 (6) 6 (4) 1 (1) 1 (1) 1 (1)
HPV81 12 (9) 11 (8) 9 (7) 0 (0) 0 (0)
HPV83 14 (10) 11 (8) 7 (5) 2 (2) 1 (1)
HPV84 21 (15) 17 (12) 12 (9) 3 (2) 0 (0)
HPV85 3 (2) 3 (2) 0 (0) 0 (0) 0 (0)
HPV86/87 14 (10) 10 (7) 10 (7) 1 (1) 0 (0)
HPV90/106 18 (13) 14 (10) 10 (7) 1 (1) 0 (0)
HPV97 1 (1) 1 (1) 1 (1) 0 (0) 0 (0)
HPV102/89 6 (4) 3 (2) 3 (2) 1 (1) 0 (0)
a Any anogenital site includes participants with samples from 1 to 3 anogenital sites.
b Anal only, anal + perianal, anal + penile/scrotal.
c Perianal only, perianal + anal, perianal + penile/scrotal.
d Penile/scrotal only, penile/scrotal + anal, penile/scrotal + perianal.
e Positive for ≥1 HPV type.
f Indicates types in the quadrivalent vaccine and nine-valent vaccine.
g Indicates types only in the nine-valent vaccine.
h We tested for 33 types individually (6, 11, 16, 18, 30, 31, 33, 34, 35, 39, 45, 51, 52, 53, 54, 56, 58, 59, 61, 62, 66, 67, 68, 70, 71, 72, 73, 81, 82, 83, 84, 85, and
97), and 8 mixtures of 2–8 types (32/42, 26/69, 57/2/27, 86/87, 90/106, 102/89, Mix1 containing 7, 13, 40, 43, 44, 55, 74, and 91, and Mix2 containing 3, 10, 28,
29, 77, 78, and 94).
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HPV type concordance between sites was relatively low (Table 4).
HPV16 was identified in 20% of young men at any site, but in only 6%
at both the anal and perianal sites, 2% at the anal and penile/scrotal
sites, 1% at the perianal and penile/scrotal sites, and 1% at the anal,
perianal and penile/scrotal sites. In each of the 4 cases in which HPV16
or HPV18 were identified at more than one site and genotype variant
results were available, analysis revealed the same variant at both sites.
There was no concordance between anogenital and oral HPV types.
Generally, the highest concordance for all types was between the con-
tiguous anal and perianal sites.
Multivariable logistic regression models identified participant
characteristics independently associated with infection with at least one
HPV type targeted by the 9-valent vaccine (Table 5). Separate models
assessed HPV infection at each anogenital site and any site. After ad-
justing for race and current smoking, younger age (18–21 years vs.
22–26 years) was significantly associated with 9-valent anal HPV in-
fection (odds ratio [OR]=3.46). Number of receptive anal sex partners
in the past 6 months was associated with perianal HPV infection
(OR=4.51 for 2+ vs. 0 partners). Current smoking was the only factor
associated with penile/scrotal HPV infection (OR=9.82). The numbers
of oral sex partners (defined as giving oral sex) and receptive anal
partners (defined as receiving anal sex) in the past 6 months were
highly correlated; therefore, for the outcome variable HPV infection at
any site, separate models were estimated that included either number of
anal or number of oral sex partners. In the multivariable model that
included receptive anal sex partners (i.e. number of partners from
whom the participant has received anal sex) but not oral sex partners,
the following characteristics were associated with HPV infection at any
site: African-American vs. White race (OR=2.67), current smoking
(OR=2.37), and number of receptive anal sex partners in the past 6
months (OR=3.47 for 2+ vs. 0 partners). In the model that included
oral sex partners but not receptive anal sex partners, the following
characteristics were associated with HPV infection at any site: African-
American vs. White rate (OR=2.97), current smoking (OR=2.52), and
number of male oral sex partners in the past 6 months (OR=4.10 for
2+ vs. 0 partners). Multivariable logistic regression models also as-
sessed participant characteristics independently associated with infec-
tion with HPV16 and/or HPV18 (Table 5). Younger age (18–21 vs.
22–26 years) was associated with perianal HPV infection (OR=4.42);
chlamydia and/or gonorrhea infection with penile/scrotal HPV
Table 3
HPV16, HPV18, and HPV31 genotype variants, by racea.
HPV16 genotype variants (N=37)b African European Unknown
N %c N %c N %c
Race White 1 10 9 90 0 0
African-American 9 38 14 58 1 4
Other 0 0 2 100 0 0
Unknown 1 100 0 0 0 0
HPV18 genotype variants (N=21)d Asian Amerindian African European
N % N % N %
Race White 2 40 1 20 2 40
African-American 2 15 5 38 6 46
Other 2 100 0 0 0 0
Unknown 0 0 0 0 1 100
HPV31 genotype variants (N=16)e A B C Unknown
N % N % N % N %
Race White 5 83 0 0 1 17 0 0
African-American 3 33 4 44 1 11 1 11
Other 1 100 0 0 0 0 0 0
a Only enrolled participants having strain variant data were included. P values were calculated for the association between race and variant using Fisher's exact
test; all were> .05. The A lineage is found worldwide while the B and C lineages are found primarily in Africa.
b Six observations belonging to five participants who were screened but not enrolled into the study were excluded in the table.
c Row percentage.
d One participant who was screened but not enrolled into the study was excluded in the table.
e Five observations belonged to four participants who were screened but not enrolled into the study were excluded in the table.
Table 4
HPV types in the 9-valent vaccine by site and concordance between sites (n=127)a.
















N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%)
HPV6 55 (43) 22 (17) 3 (2) 2 (2) 22 (17) 5 (4) 5 (4) 4 (3) 0 (0)
HPV11 24 (19) 6 (5) 3 (2) 2 (2) 10 (8) 3 (2) 3 (2) 2 (2) 0 (0)
HPV16 26 (20) 15 (12) 1 (1) 0 (0) 8 (6) 2 (2) 1 (1) 1 (1) 0 (0)
HPV18 15 (12) 7 (6) 1 (1) 0 (0) 5 (4) 0 (0) 0 (0) 0 (0) 0 (0)
HPV31 12 (9) 9 (7) 0 (0) 0 (0) 2 (2) 0 (0) 0 (0) 0 (0) 0 (0)
HPV33 12 (9) 7 (6) 0 (0) 0 (0) 5 (4) 0 (0) 0 (0) 0 (0) 0 (0)
HPV45 14 (11) 7 (6) 0 (0) 0 (0) 5 (4) 0 (0) 0 (0) 0 (0) 0 (0)
HPV52 14 (11) 6 (5) 1 (1) 0 (0) 6 (5) 1 (1) 1 (1) 1 (1) 0 (0)
HPV58 22 (17) 11 (9) 2 (2) 1 (1) 5 (4) 0 (0) 0 (0) 0 (0) 0 (0)
Any 9-valent
type
99 (80) 30 (24) 3 (2) 1 (1) 54 (43) 14 (11) 13 (10) 12 (9) 0 (0)
a Analyses only include participants who had evaluable HPV results at all 4 anatomical sites (anal, perianal, penile/scrotal, oral).
b Type was detected at any site.
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Table 5
Results of univariable and multivariable logistic regression models: unadjusted and adjusted (for participant characteristics) odds of infection with HPV types
included in the 9-valent HPV vaccine (Model 1) and infection with HPV16/18 (Model 2), at the anal, perianal, penile/scrotal, and any sitea.




Unadjusted ORb Adjusted ORd
(95% CIc) (95% CI)
Model 1: Outcome variable is infection with HPV types included in the 9-valent vaccine
Anal site (N=137)
Age (years) 18–21 27 85 3.29 (1.06–10.18) 3.46 (1.08–11.11)
22–26 110 64 1.0 –
Race African-American 77 75 1.88 (0.84–4.22) 1.80 (0.76–4.27)
Other 18 50 0.62 (0.20–1.88) 0.54 (0.16–1.77)
White 42 62 1.0 –
Smoking (current) Yes 60 75 2.0 (0.94–4.26) 2.17 (0.97–4.85)
No 70 60 1.0 –
Number of receptive anal male sex
partners, past 6 months
2+ 55 78 2.56 (0.91–7.19)
1 51 61 1.11 (0.41–2.97)
0 24 58 1.0 –
Perianal site (N=136)
Age (years) 18–21 27 59 2.23 (0.95–5.27)
22–26 109 39 1.0 –
Number of receptive anal male sex
partners, past 6 months
2+ 57 61 4.51 (1.54–13.18) 4.51 (1.54–13.18)
1 49 35 1.51 (0.50–4.53) 1.51 (0.50–4.53)
0 23 26 1.0 –
Penile/scrotal site (N=133)
Smoking (current) Yes 58 22 9.82 (2.12–45.61) 9.82 (2.12–45.61)
No 70 3 1.0 –
Any site (N=141) Model 1a Model 1b
Age (years) 18–21 28 86 3.04 (0.98–9.39)
22–26 113 66 1.0
Race African-American 78 81 2.80 (1.23–6.36) 2.67 (1.11–6.42) 2.97 (1.22–7.22)
Other 18 50 0.67 (0.22–2.0) 0.57 (0.16–2.0) 0.58 (0.16–2.04)
White 45 60 1.0
Smoking (current) Yes 62 79 2.40 (1.11–5.20) 2.37 (1.03–5.48) 2.52 (1.06–5.97)
No 72 61 1.0
Number of receptive anal male sex
partners, past 6 months
2+ 57 82 3.69 (1.30–10.49) 3.47 (1.16–10.37)
1 52 62 1.26 (0.48–3.31) 1.29 (0.46–3.64)
0 25 56 1.0
Number of male oral sex partners in
past 6 months
2+ 66 80 2.72 (0.82–9.01) 4.10 (1.13–14.91)
1 52 60 0.98 (0.31–3.18) 1.53 (0.43–5.53)
0 15 60 1.0
Model 2: Outcome variable is infection with HPV16/18
Anal site (N=137)
Number of receptive anal male sex
partners, past 6 months
2+ 55 36 4.0 (1.06–15.10) 6.66 (0.93–47.69)
1 51 18 1.50 (0.37–6.13) 2.87 (0.39–21.09)
0 24 13 1.0 –
Frequency of condom use during
oral sex, past 6 months
Never 80 24 2.03 (0.42–9.78) 0.51 (0.05–5.02)
Mostly/Half/
Occasionally
23 17 1.37 (0.22–8.6) 0.39 (0.03–4.66)
Every time 12 58 9.1 (1.39–59.62) 2.85 (0.28–28.60)
No oral sex 15 13 1.0 –
Perianal site (N=136)
Age (years) 18–21 27 26 4.42 (1.44–13.57) 4.42 (1.44–13.57)
22–26 109 7 1.0 1.0
Penile/scrotal site (N=130)
Sexual intercourse with a male
partner, past 6 months
Yes 117 1 0.09 (0.01–1.48)
No 11 9 1.0 –
Chlamydia and/or gonorrhea
infection (current)
Yes 6 17 22.46 (1.78–282.72) 22.46 (1.78–282.72)
No 124 1 1.0 1.0
CD4+ T-cell count ≤350 12 8 10.91 (0.64–186.67)
> 350 121 1 1.0 –
Any site (N=141) Model 2a Model 2b
Age (years) 18–21 28 39 2.40 (0.99–5.80) 2.29 (0.90–5.79)
22–26 113 21 1.0 – –
Number of receptive anal male sex
partners, past 6 months
2+ 57 37 4.28 (1.14–16.03) 7.27 (1.04–50.59) 3.76 (0.99–14.29)
1 52 17 1.54 (0.38–6.25) 2.97 (0.41–21.26) 1.33 (0.32–5.52)
0 25 12 1.0 – –
(continued on next page)
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infection (OR=22.46); and number of receptive anal sex partners in the
past 6 months at any site (OR=7.27 for 2+ vs. 0 partners), but was no
longer significant in a second model adjusting for age instead of
condom use. No variables were associated with anal HPV.
4. Discussion
In this study, we examined anogenital and oral HPV DNA detection
in young HIV-infected MSM without HSIL, prior to HPV vaccination.
The study is novel in that we not only determined the prevalence of
anogenital HPV at multiple sites in a unique population of young HIV-
infected MSM at high risk for HPV, but also determined the prevalence
of oral HPV and HPV genotype variants; examined concordance be-
tween HPV at anogenital and oral sites; and determined demographic,
behavioral, immunologic, virologic factors associated with having one
or more HPV types in the 9-valent HPV vaccine and HPV16/18.
Almost all young men in this study sample were infected with at
least one HPV type at any anogenital site. The high prevalence rate is
especially notable since men with biopsy-proven HSIL at baseline were
excluded. Most previous studies assessing anogenital HPV in HIV-in-
fected MSM were conducted in older men, and demonstrated an HPV
prevalence of greater than 90% [1,10,11,16,17,19,24,27,38]. Pre-
valence rates of anogenital HPV are lower in HIV-uninfected MSM, yet
most studies demonstrate anal HPV infection rates that are still high;
typically 65–70% [1,16,19,22,24,27,37,41]. Furthermore, 57% of par-
ticipants were infected with at least one 4-valent vaccine type, and 70%
with at least one 9-valent vaccine type. These findings all highlight the
importance of educating clinicians and parents about the urgency of
vaccinating boys in the target age range of 11–12 years, prior to HPV
exposure, to decrease anal cancer incidence and mortality.
Despite the high overall HPV prevalence, 82% of young men in this
study were not infected with HPV16 and 89% were not infected with
HPV18, the types that cause most anal cancers in MSM [8]. Since this
was a vaccine efficacy study, MSM with HSIL were excluded from
participation (and offered vaccination outside the study); therefore, the
prevalence of anogenital HPV16 or 18 infection may have been even
higher in this population of young HIV-infected MSM had they been
included in the analysis. However, these data suggest that many young
HIV-infected MSM would still likely benefit from vaccination and
should be targeted for vaccination, despite their high risk for infection
with non-vaccine HPV types. Effective public health messaging is
needed to ensure that clinicians, parents, and young men understand
that vaccination may be beneficial for young MSM regardless of HIV
status and sexual experience. However, vaccinating prior to HPV ex-
posure is expected to be far more effective in preventing HPV-related
cancers; therefore, the approach of vaccinating sexually active MSM
should not take precedent over a gender neutral vaccination program
and a focus on vaccinating children prior to sexual initiation.
Oral HPV prevalence was low in this study sample: 6% of partici-
pants were positive for at least one oral HPV type, and none were po-
sitive for a 9-valent vaccine type including HPV16. In a recent meta-
analysis of oral HPV infection in MSM, the pooled prevalence of oral
Table 5 (continued)




Unadjusted ORb Adjusted ORd
(95% CIc) (95% CI)
Model 1: Outcome variable is infection with HPV types included in the 9-valent vaccine
Anal site (N=137)
Frequency of condom use during
oral sex, past 6 months
Never 83 24 2.06 (0.43–9.93) 0.49 (0.05–4.75)
Mostly/Half/
Occasionally
24 17 1.30 (0.21–8.15) 0.34 (0.03–4.00)
Every time 12 58 9.1 (1.39–59.62) 2.71 (0.27–27.08)
No oral sex 15 13 1.0 –
a Only those variables associated with the outcome variable at p< .10 in univariable analyses are included in the table. Variables included in univariable analyses
for both Model 1 and Model 2 included: age, race, Hispanic ethnicity, last receptive anal intercourse, current smoking, last anal sexual intercourse with a male
partner, last sexual intercourse with a male partner, number of male sexual partners in the past six months, number of anal male sexual partners in the past 6 months,
frequency of condom use during receptive anal intercourse, number of oral male sex partners in the past six months (to whom the participant gave oral sex),




d Model 1 (outcome variable 9-valent HPV infection): The final model for anal HPV included age, race and smoking, as the number of anal sex partners in past 6
months was not significant at p<0.10 in the multivariable model after adjusting for age, race, and smoking. The final model for perianal HPV included number of
anal sex partners in past 6 months, as age was not significant at p<0.10 in the multivariable model after adjusting for the number of anal sex partners. The final
models for any site included the following variables. Model 1a included race, smoking, and the number of anal sex partners in past 6 months, as age was not
significant at p< 0.10 in the multivariable model after adjusting for race, smoking, and the number of anal sex partners. Model 1b included race, smoking, and the
number of oral sex partners in past 6 months, as age was not significant at p< 0.10 in the multivariable model after adjusting for race, smoking, and the number of
anal sex partners. The reason two models were estimated is that number of anal sex partners in the past 6 months and number of oral sex partners in the past 6 months
were highly correlated; therefore, separate multivariable logistic regression models were estimated that included either number of anal sex partners (Model 1a) or
number of oral sex partners in the past 6 months (Model 1b). In a multivariable model including both anal and oral sex partners, neither was significantly associated
with HPV. Model 2 (outcome variable HPV16/18): The final model for penile/scrotal HPV 16/18 included current Chlamydia or gonorrhea infection, as last sexual
intercourse with a male partner was not significant at p<0.10 in the multivariable model after adjusting for current Chlamydia or gonorrhea infection and/or CD4
cell count; also, CD4 cell count was not significant at p<0.10 in the multivariable model after adjusting for last sexual intercourse with a male partner and/or
current Chlamydia or gonorrhea infection. In the model predicting HPV16/18 at any site that contained all variables associated with the outcome at p< .10 (age,
number of anal male sexual partners in the past 6 months, and frequency of condom use during oral sex), none of the variables were associated with the outcome at
p< .05 but the p value was borderline significant (p=.055) for number of anal sexual partners. Therefore, we estimated two separate models, both of which included
number of anal sexual partners. Model 2a included number of anal sexual partners in the past 6 months and frequency of condom use during oral sex. Model 2b
included number of anal male sexual partners in the past 6 months and age.
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HPV16 was 3.0% in HIV-negative and 4.7% in HIV-positive MSM [15]:
it is unclear why oral HPV16 prevalence was lower in our population.
Although the efficacy of HPV vaccines in preventing oral HPV has not
been studied prospectively in clinical trials, the vaccine is expected to
be effective in preventing oral HPV [12]. A recent study conducted in a
national sample of young adults demonstrated that from 2001 to 2014,
the prevalence of oral vaccine-type HPV infections was significantly
reduced in vaccinated vs. unvaccinated individuals, corresponding to
an estimated 88.2% reduction in prevalence, despite relatively low
vaccination rates [9].
Concordance between anogenital sites and between anogenital and
oral sites was relatively low in this study. Previous studies similarly
have demonstrated low concordance [15,34,41] or no concordance
[14] between anogenital and oral sites in MSM. The findings suggest
that self-inoculation between anogenital sites or between oral and an-
ogenital sites may be uncommon, that different anogenital sites may
vary in terms of their susceptibility to HPV infection, or that the ability
to detect the same HPV type from different sampling sites may vary
[41]. Conversely, genotype variant analysis showed that the same
variants were present when the same HPV type was found at more than
one site. Our findings are difficult to interpret given the small number
of individuals with concordant type infection at multiple sites, and the
fact that individuals with the highest risk for multisite disease (those
with HSIL) were excluded, but this finding could be consistent with
exposure to a given HPV genotype variant from the same partner at
multiple anatomic sites. The prevalence of oral HPV was lower than in
some previous studies, which may indicate an issue with detection.
Since HPV16, HPV18, and HPV31 genotype variants were identified
in a relatively small number of participants, our ability is limited to
draw conclusions about the prevalence of genotype variants in HIV-
infected MSM and their association with race. However, we did find
that genotype variants tended to differ by race; e.g. African HPV16
variants were found more commonly among African-American vs. other
participants. Few studies have examined HPV16 genotype variants in
HIV-infected MSM but these have demonstrated that European variants
are the most common [23,42,43]. Further study is needed to examine
genotype variants in HIV-infected MSM, given their possible association
with HPV persistence and the increased risk of cancer with non-Eur-
opean variants [7,26,29,39,45]. Factors associated with anogenital
vaccine-type HPV differed by site, but included younger age, African-
American race, recent smoking, concurrent urethral chlamydia or go-
norrhea infection, and number of recent receptive anal and oral sex
partners. These findings are consistent with risk factors for anogenital
HPV identified in previous studies. The main outcome variable in this
study, 9-valent vaccine-type HPV, differed from previous studies con-
ducted prior to 9-valent HPV vaccine introduction; however, number of
receptive anal sex partners is one of the factors most consistently as-
sociated with anal HPV across studies, regardless of the outcome vari-
able [11,17,24,28,41]. The implications are that education of young
HIV-infected MSM should include counseling about the importance of
avoiding smoking or smoking cessation, and practicing safer sexual
behaviors including limiting the number of partners with whom they
have receptive anal sex.
This study has several limitations. Although participants were re-
cruited from sites across the U.S., the overall study sample was small
which limits the power to detect associations between risk factors and
HPV outcomes. Self-reported behaviors are subject to bias. Participants
were HIV-infected MSM without anal HSIL who also generally had low
HIV viral load and high CD4+T-cell count and who were willing to
participate in a clinical trial. Study participants with these character-
istics may represent a group at lower risk for STIs than the general
population of HIV-infected young MSM.
5. Conclusions
This study of pre-vaccination exposure to anogenital and oral HPV
in young HIV-infected MSM without HSIL demonstrated that while the
prevalence of any HPV type was high, most young HIV-infected MSM
who did not have HSIL were negative for HPV16 and HPV18. Our data
not only suggest that this group would potentially benefit from HPV
vaccination and should be aggressively targeted for vaccination, but
also that vaccination of 11–12 year-old boys prior to sexual initiation
should be a priority. Although this study focused on HIV-infected MSM
without HSIL at screening, all HIV-infected men age 26 and under
should be vaccinated since the vaccine may prevent incident HSIL
caused by HPV types to which they have not yet been exposed. Young
HIV-infected MSM should also be educated about the importance of
avoiding smoking and the risks associated with engaging in receptive
anal sex with multiple partners.
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